The hardest part of obesity treatment is keeping the weight off, and a small implant may be how one company tries to change that. The drug it would deliver is semaglutide, a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone the gut releases after eating that reduces appetite. Vivani Medical is developing the implant, using the same molecule that Novo Nordisk puts into Wegovy, its injectable obesity drug, and Ozempic, its injectable diabetes treatment.
What continuous delivery is supposed to fix
Wegovy and Ozempic are injected. A patient, or a clinician, must administer them on a schedule. An implant handles that itself. Vivani Medical's stated aim is weight maintenance. Losing weight with GLP-1 drugs is achievable. Keeping it off is the harder part, and a device that keeps semaglutide releasing steadily without patient management would, in principle, address exactly that.
The word "bet" in how this device is framed is accurate. This is development, not delivery. No clinical trial data, regulatory timeline, or commercial launch date appears in the available information.
The molecule, the brands, and who owns what
Semaglutide is the active compound. Novo Nordisk holds the Wegovy and Ozempic brand names. Vivani Medical is developing a new delivery format for the same molecule. The source describes no licensing arrangement between the two companies.
Wegovy targets obesity. Ozempic targets diabetes. Both carry semaglutide as the active ingredient. That the same compound anchors two commercial products across two distinct disease states makes it an attractive molecule for a third party to build a delivery device around.
What the reporting leaves open
No efficacy data, no human trial results, and no device specifications beyond "tiny" appear in the source. Vivani Medical is in development. How far along that development sits, the reporting does not say.